These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18771083)

  • 1. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.
    Jia SF; Guan H; Duan X; Kleinerman ES
    J Exp Ther Oncol; 2008; 7(2):89-97. PubMed ID: 18771083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.
    Huang G; Nishimoto K; Zhou Z; Hughes D; Kleinerman ES
    Cancer Res; 2012 Feb; 72(4):908-16. PubMed ID: 22186140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
    Lafleur EA; Koshkina NV; Stewart J; Jia SF; Worth LL; Duan X; Kleinerman ES
    Clin Cancer Res; 2004 Dec; 10(23):8114-9. PubMed ID: 15585647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
    Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES
    Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation.
    Huang G; Koshkina NV; Kleinerman ES
    Oncol Res; 2009; 18(1):31-9. PubMed ID: 19911702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.
    Gutiérrez LM; Valenzuela Alvarez M; Yang Y; Spinelli F; Cantero MJ; Alaniz L; García MG; Kleinerman ES; Correa A; Bolontrade MF
    Apoptosis; 2021 Aug; 26(7-8):447-459. PubMed ID: 34024019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
    Koshkina N; Yang Y; Kleinerman ES
    Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells.
    Duan X; Jia SF; Zhou Z; Langley RR; Bolontrade MF; Kleinerman ES
    Clin Exp Metastasis; 2004; 21(8):747-53. PubMed ID: 16035619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating
    Yang Y; Huang G; Zhou Z; Fewell JG; Kleinerman ES
    Mol Cancer Ther; 2018 Jan; 17(1):130-139. PubMed ID: 29079708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
    Gordon N; Kleinerman ES
    J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
    Koshkina NV; Rao-Bindal K; Kleinerman ES
    Cancer; 2011 Aug; 117(15):3457-67. PubMed ID: 21287529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
    Huang G; Nishimoto K; Yang Y; Kleinerman ES
    Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
    Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
    Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells.
    Liao YY; Tsai HC; Chou PY; Wang SW; Chen HT; Lin YM; Chiang IP; Chang TM; Hsu SK; Chou MC; Tang CH; Fong YC
    Oncotarget; 2016 Jan; 7(4):4310-25. PubMed ID: 26713602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
    Gordon N; Kleinerman ES
    Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fas expression inversely correlates with metastatic potential in osteosarcoma cells.
    Worth LL; Lafleur EA; Jia SF; Kleinerman ES
    Oncol Rep; 2002; 9(4):823-7. PubMed ID: 12066216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.
    Koshkina NV; Kleinerman ES
    Int J Cancer; 2005 Sep; 116(3):458-63. PubMed ID: 15800950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of FAS Receptor Methylation in Osteosarcoma Metastasis.
    Sun JM; Chow WY; Xu G; Hicks MJ; Nakka M; Shen J; Ng PKS; Taylor AM; Yu A; Farrar JE; Barkauskas DA; Gorlick R; Guidry Auvil JM; Gerhard D; Meltzer P; Guerra R; Man TK; Lau CC; On Behalf Of The Target Osteosarcoma Consortium
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered morphology, nuclear stability and adhesion of highly metastatic derivatives of osteoblast-like SAOS-2 osteosarcoma cells.
    Muff R; Nigg N; Gruber P; Walters D; Born W; Fuchs B
    Anticancer Res; 2007; 27(6B):3973-9. PubMed ID: 18225558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy.
    Tanaka T; Yui Y; Naka N; Wakamatsu T; Yoshioka K; Araki N; Yoshikawa H; Itoh K
    Clin Exp Metastasis; 2013 Apr; 30(4):369-79. PubMed ID: 23076771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.